Transfusion and Apheresis Science
Volume 37, Issue 1 , Pages 49-56 , August 2007

The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma

  • Matthew Seftel

      Affiliations

    • Corresponding Author InformationCorresponding author. Present address: Department of Medical Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada. Tel.: +204 787 3594; fax: +204 786 0196.
    • ,
  • Morel Rubinger

Received 11 April 2007 ,Accepted 24 April 2007.

References 

  1. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical trials group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634–4642
  2. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: Report of an Intergroup Trial. J Clin Oncol. 2003;21(4):607–614
  3. Connors JM. Evolving approaches to primary treatment of Hodgkin lymphoma. Hematology. 2005;2005(1):239–244
  4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514
  5. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP–ABVD. J Clin Oncol. 1997;15(2):528–534
  6. Diehl V, Thomas RK, Re D. Part II: Hodgkin’s lymphoma – diagnosis and treatment. Lancet Oncol. 2004/1;5(1):19–26
  7. Bartlett NL, Smukler AJ. Management of advanced stage Hodgkin’s lymphoma. Cancer Treat Res. 2006;131:333–352
  8. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2002;20(1):221–230
  9. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: The low probability for cure. J Clin Oncol. 1992;10(2):210–218
  10. Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol. 2005;23(26):6400–6408
  11. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96(4):1280–1286
  12. Josting A, Nogova L, Franklin J, Glossmann J, Eich HT, Sieber M, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7):1522–1529
  13. Josting A. Autologous transplantation in relapsed and refractory Hodgkin’s disease. Eur J Haematol. 2005;75(s66):141–145
  14. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, et al. High dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23(31):7994–8002
  15. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054
  16. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous hematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002/6/15;359(9323):2065–2071
  17. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, et al. High dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: Importance of disease status at transplant. J Clin Oncol. 1993;1(4):704–711
  18. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol. 2004;124(5):645–652
  19. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: Results of the Groupe d’etudes des Lymphomes de l’adulte H89 trial. J Clin Oncol. 2002;20(2):467–475
  20. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625
  21. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: Biology and treatment strategies for primary, refractory, and relapsed disease. Hematology. 2003;2003(1):225–247
  22. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96(4):1280–1286
  23. Prete A, Bonetti F, Rondelli R, Cesaro S, Dallorso S, Favre C, et al. High dose therapy (HDCT) and autologous haematopoietic stem cell transplantation (aSCT) in paediatric patients with recurrent or refractory Hodgkin’s disease (HD): Results and outcome. ASH Annual Meeting Abstracts. 2005;106(11):2088
  24. Josting A, Rudolph C, Mapara M, Glossmann JP, Sienawski M, Sieber M, et al. Cologne high dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16(1):116–123
  25. Clinicaltrials.gov. National Cancer Institute: US National Institute of Health. 2006, April 26 2006. Available from: http://clinicaltrials.gov/ct/show/NCT00265889?order=5.
  26. Clinicaltrials.gov. National Cancer Institute: U.S National Institute of Health. 2006. April 26 2006. Available from: http://clinicaltrials.gov/ct/show/NCT00233987?order=6.
  27. Fung HC, Stiff P, Nademanee A, Smith E, Cutrone C, Parthasarathy M, et al. Final report on tandem autologous stem cell transplantation for patients with primary progressive or poor risk recurrent Hodgkin Lymphoma – A two institution study. ASH Annual Meeting Abstracts. 2005;106(11):2071
  28. Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14(12):1762–1767
  29. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer. 2006;106(2):353–360
  30. Reece D, Connors J, Spinelli J, Barnett M, Fairey R, Klingemann H, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide±cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy [see comments]. Blood. 1994;83(5):1193–1199
  31. Maness LJ, Loberiza FR, Sanger W, DeVetten MP, Bierman P, Bociek G, et al. Can elimination of total body irradiation (TBI) in conditioning regimens for autologous stem cell transplantation (SCT) in patients with Hodgkin and non-Hodgkin lymphoma decrease the risk of secondary AML/MDS(sAML/MDS)? A retrospective case-control study at the university of Nebraska medical center. ASH Annual Meeting Abstracts. 2005;106(11):682
  32. Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E, et al. Twelve years experience with high dose therapy and autologous stem cell transplantation for high risk Hodgkin’s disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma. 1996;21(1–2):63–70
  33. Saghatchian M, Djeridane M, Escoffre-Barbe M, Desablens B, Foussard C, Lacotte-Thierry L, et al. Very high risk Hodgkin’s disease (HD): ABVD (4 cycles) plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles)(INT–CT) and RT.; four-year results of the GOELAMS H97-GM multicentric randomized trial. Proc Am Soc Clin Oncol. 2002;21(abstr 1051):263a
  34. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP–ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–2395
  35. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a Graft-versus-Lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77(3):649–653
  36. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, et al. Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol. 2001;19(23):4314–4321
  37. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14(4):1291–1296
  38. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31(8):667–678
  39. Thomson KJ, Peggs KS, Smith P, Chopra R, Cavet J, Hunter A, et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin’s lymphoma relapsing post-autologous transplantation. ASH Annual Meeting Abstracts. 2005;106(11):657
  40. Robinson SP, Schmitz N, Taghipour G, Sureda A. Reduced intensity allogeneic stem cell transplantation for Hodgkin’s disease. Outcome depends primarily on disease status at the time of transplantation. ASH Annual Meeting Abstracts. 2004;104(11):2322
  41. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a Graft-versus-Hodgkin’s-lymphoma effect after reduced intensity allogeneic transplantation. Lancet. 2005;365(9475):1934–1941
  42. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol. Biology of Blood and Marrow Transplantation. 2006/2;12(2):172–183
  43. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, et al. Reduced intensity allogeneic stem cell transplantation in relapsed and refractory hodgkin’s disease: Low transplant related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35(10):943–951
  44. Burroughs LM, Maris MB, Sandmaier BM, Leisenring W, Jain Stuart M, Niederwieser D, et al. HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). Biol Blood Marrow Transplant. 2004;10(Supplement 1):73–74

PII: S1473-0502(07)00095-X

doi: 10.1016/j.transci.2007.04.005

Transfusion and Apheresis Science
Volume 37, Issue 1 , Pages 49-56 , August 2007

Article Tools

* Image Usage & Resolution